As George Bernard Shaw once said, "Nothing is ever done in this world until men are prepared to kill one another if it is not done." While accidental fatalities, even those caused by preventable mistakes and human errors, are a far cry from murder, Don Berwick, MD, has seen enough death. He's also heard enough rhetoric about ways to improve healthcare quality.
Read More
Clinical news updates from the 2004 AHA Scientific Sessions
January 1st 2005The American Heart Association (AHA) Scientific Sessions comprise the largest meeting of its kind held in the cardiovascular field, with several thousand presentations given each year. The recently concluded 2004 AHA Scientific Sessions, which took place in New Orleans, included presentations of trials that evaluated potential therapeutic compounds, as well as widely used and accepted compounds in new dosages or combinations, for the treatment of cardiovascular disorders. The compilation of clinical news that follows focuses on the cardiovascular pharmacotherapy trials of greatest interest to formulary decision-makers, including: CREATE, PEACE, A-HeFT, PROTECT, CLEAR Platelets, DIPOM, GEMINI, SHIELD, and RIO-NA.
Read More
Focus on posaconazole: A novel triazole antifungal for the treatment of invasive fungal infections
January 1st 2005Serious infections due to the Aspergillus and Candida species and other filamentous fungi have emerged as an increasing cause of infectious morbidity and mortality in the United States and globally. The most notable explanation for this increase is a rise in the number of immunocompromised patients due to advances in transplantation, the emergence and prevalence of Acquired Immunodeficiency Syndrome (AIDS), and an increase in the number of invasive surgical procedures. 1-3 Treatment of these infections with currently available standard antifungal agents such as amphotericin B, itraconazole, and fluconazole still results in an unacceptably high associated mortality. 3. Furthermore, many of these antifungal agents have limitations, including dose-limiting toxicity, drug-drug interactions, and fungal resistance. 4-10
Read More
SHORTLY AFTER the Allied victory in 1945, Albert Einstein produced one of his most-famous quotes: "I do not know what will be used in the next world war?assuming there will be another one?but the fourth world war will be fought with stones."An ominous statement from a truly brilliant man, to be sure. Hopefully, we'll never have to find out, but even if the next war is fought with clubs and rocks, there will still be a need for medical specialists to take care of the wounded.
Read More
Regulatory limitations impact annual financial decisions
January 1st 2005We are approaching the time of year when health insurers are beginning to calculate loss ratios and compile other financial data in order to evaluate the performance of their book of business. They will evaluate each market segment and product line, and make underwriting and rating decisions as to each.
Read More
Optimizing treatment outcomes dependent on appropriate categorization of insomnia
December 2nd 2004There is a growing interest in the study of insomnia; this is reflected in emerging trends in clinical management and increased research. One key question is being asked: Is insomnia a symptom or a disease?
Read More